000			03451cam a2200349 a 4500
003			EG-GiCUC
005			20250223032529.0
008			200227s2019 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.04.M.Sc.2019.Mo.S
100	0		_aMohammed Samir Mohammed Alsayed Alnims
245	1	0	_aSix months clinical and echocardiographic outcome of angiotensin receptor-neprilysin inhibitor LCZ696 therapy in heart failure patients with reduced ejection fraction / _cMohammed Samir Mohammed Alsayed Alnims ; Supervised Magdy Abdelhamid Abdelaziz , Mohamed Abdelmeguid Mahdy , Ahmed Shehata Mohamed
246	1	5	_aفى مرضى هبوط عضلة القلب (LCZ696) النتائج الإكلينيكية و بالموجات الصوتية على القلب بعد ستة أشهر من العلاج بمثبط مستقبل الأنجيوتنسين {u٢٠١٣} النيبريلايسين
260			_aCairo : _bMohammed Samir Mohammed Alsayed Alnims , _c2019
300			_a139 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Cardiology
520			_aBackground: The discovery and introduction of Neprilysin inhibitor in treating chronic heart failure (New York heart association class II{u2013}IV) with reduced ejection fraction (HFrEF) is a remarkable landmark in therapy. The clinical outcome of reducing the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure was demonstrated in PARADIGM-HF trial. These benefits may be related to effects on hemodynamics and cardiac remodeling. Objectives: To evaluate the clinical and echocardiographic outcome of Sacubitril/Valsartan therapy in HFrEF patients, in addition to its efficacy in reducing mortality and rehospitalisation rate. Methods: We performed a single center, prospective, cohort study of HFrEF patients (n=100) who were treated with Sacubitril/Valsartan for a median duration of 6 months. Clinical and echocardiographic parameters were reviewed at baseline and after 6 months. Results: Among 100 patients (median age, 56.5 years; 76% men), at 6 months, improvement of NYHA class has occurred in 83.9% patients (P < 0.001) and only 16.1% remain unchanged. The median LVEF was 30% and increased to 35% after treatment (P < 0.001), about 51.6% patients showed increase in LVEF at least by 5% and 23.7% showed increase in LVEF at least by 10%. Left ventricular diastolic volume decreased from a median baseline 179 to 150ml (P < 0.001), and left ventricular systolic volume decreased from a median baseline 125 to 91ml (P <0.001). About 84 (84%) patients were hospitalized before starting the treatment, and only 33 (35.9%) patients were rehospitalized after initiating the treatment during the follow up period (P=.007).The most frequent adverse events were hypotension (7.5%), hyperkalemia (7.5%), and worsening kidney function 6.5%
530			_aIssued also as CD
653		4	_aHeart failure with reduced ejection fraction (HFrEF)
653		4	_aLVEF
653		4	_aSacubitril / Valsartan
700	0		_aAhmed Shehata Mohamed , _eSupervisor
700	0		_aMagdy Abdelhamid Abdelaziz , _eSupervisor
700	0		_aMohamed Abdelmeguid Mahdy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c76805 _d76805